Table 2.
Demographic and clinical characteristics in terms of pregnancy outcome
| Favorable n=117 | Unfavorable n=33 | P | |
|---|---|---|---|
| Age | 0.4 | ||
| <35 years old | 73 (62.4%) | 23 (69.7%) | |
| >35 years old | 44 (37.6%) | 10 (30.3%) | |
| Gravid | 0.4 | ||
| 1 | 28 (23.9%%) | 11 (33.3%) | |
| 2 | 38 (32.5%) | 11 (33.3%) | |
| 3 and more | 51 (43.6%) | 11 (33.3%) | |
| Gestational age at the time of admission | 0.1 | ||
| <24 | 34 (29.1%) | 6 (18.2%) | |
| 24-32 | 53 (45.3%) | 13 (39.4%) | |
| >32 | 30 (25.6%) | 14 (42.4%) | |
| Sign and symptoms | |||
| Dyspnea | 75 (64.1%) | 28 (84.8%) | 0.03 |
| Nausea/Vomiting | 14 (12%) | 2 (6.1%) | 0.5 |
| Neurologic symptoms | 22 (18.8%) | 3 (9.1%) | 0.2 |
| Cough | 86 (73.5%) | 26 (78.8%) | 0.5 |
| Fever | 63 (53.8%) | 20 (60.6%) | 0.4 |
| Myalgia | 49 (41.9%) | 11 (33.3%) | 0.3 |
| O2 saturation at the time of admission | 0.06 | ||
| ≥93% | 41 (35%) | 6 (18.2%) | |
| <93% | 76 (65%) | 27 (81.8%) | |
| O2 support at the time of admission | 0.000 | ||
| Low-flow oxygen | 71 (60.7%) | 8 (24.2%) | |
| High-flow oxygen/NIPPV | 46 (39.3%) | 21 (63.6%) | |
| Intubated | 0 (0%) | 4 (12.1%) | |
| Laboratory results at the time of admission | |||
| WBC | |||
| <4 (103/µL) | 8 (6.8%) | 1 (3.0%) | 0.1 |
| 4-14 (103/µL) | 106 (90.6%) | 29 (87.9%) | |
| >14 (103/µL) | 3 (2.6%) | 3 (9.1%) | |
| Neut, ≥12 (103/µL) | 3 (2.6%) | 3 (9.1%) | 0.1 |
| Lymph, <0.8 (103/µL) | 34 (29.1%) | 7 (21.2%) | 0.3 |
| Hb <11 (g/dl) | 53 (45.3%) | 10 (30.3%) | 0.1 |
| Plat <150 (103/µL) | 34 (29. %1) | 10 (30.3%) | 0.8 |
| ALT >35 (U/L) | 52 (44.4%) | 16 (48.5%) | 0.6 |
| AST >35 (U/L | 58 (49.6%) | 23 (69.7%) | 0.04 |
| LDH >500 (U/L) | 54 (46.2%) | 18 (54.5%) | 0.3 |
| D-dimer >1000 (ng/ml) | 71 (60.7%) | 19 (57.6%) | 0.7 |
| Fr >500 (µg/L) | 13 (11.1%) | 3 (9.1%) | 0.7 |
| Cr >0.8 (mg/dl) | 5 (4.3%) | 4 (12.1%) | 0.1 |
| ICU admission | 0.000 | ||
| Yes | 32 (27.4%) | 22 (66.7%) | |
| No | 85 (72.6%) | 11 (33.3%) | |
| Days between symptom onset and admission, Median (IQR) | 5 (4-6.5) | 6 (5-7) | 0.02 |
| Days between symptom onset and Remdesivir prescription, Median (IQR) | 5 (4-7) | 6 (5-7) | 0.008 |
| Hospital stay, days Median (IQR) | 6 (6-8) | 10 (7-14.5) | 0.000 |
| Remdesivir complications (LFT rise) | 43 (36.8%) | 14 (42.4%) | 0.5 |
Data are presented as numbers (percentages) unless otherwise stated. Alt: Alanine transaminase; Ast: Aspartate transaminase; Cr: Creatininin; CRP: C-Reactive Protein; Fr: Ferritin; Hb: Hemoglobin; ICU: Intensive Care unit; IQR: Inter Quartile Range; LDH: Lactate dehydrogenase; LFT: Liver Function Test; Lymph: Lymphocyte; Neut: Neutrophil; Plt: Platelet; WBC: White Blood Cells